Breaking News
Get 50% Off 0
🚀 June’s AI-picked stocks soar, with Adobe +18.1% in 11 days. Don’t miss July’s upcoming picks. Unlock full list
Close

Relief Therapeutics Holding SA (RLFB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.1300 +0.0100    +0.89%
- Delayed Data. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH1251125998 
VALOR:  125112599
  • Volume: 1,945
  • Bid/Ask: 1.1100 / 1.1300
  • Day's Range: 1.1100 - 1.1300
Relief Therapeutics 1.1300 +0.0100 +0.89%

RLFB Income Statement

 
Featured here, the Income Statement (earnings report) for Relief Therapeutics Holding SA, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Advanced Income Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Revenue 1.5 1.5 1.51 1.51
Revenue 1.5 - 1.51 1.51
Other Revenue, Total - - - -
Cost of Revenue, Total 0.526 0.526 0.434 0.434
Gross Profit 0.98 0.98 1.08 1.08
Total Operating Expenses 5.63 5.63 7.31 7.31
Selling/General/Admin. Expenses, Total 4.13 4.13 5.58 5.58
Research & Development 0.198 0.198 0.466 0.466
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating -0.007 -0.007 -0.006 -0.006
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 0.778 0.778 0.834 0.834
Operating Income -4.12 -4.12 -5.8 -5.8
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets 0.062 0.062 - -
Other, Net 19.59 19.59 26.27 26.27
Net Income Before Taxes -23.77 - -32.07 -32.07
Provision for Income Taxes - - -3.82 -3.82
Net Income After Taxes - - -28.25 -28.25
Minority Interest - - - -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items - - -28.25 -28.25
Total Extraordinary Items - - - -
Net Income - - -28.25 -28.25
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items - - -28.25 -28.25
Dilution Adjustment - - -0.001 -0.001
Diluted Net Income - - -28.25 -28.25
Diluted Weighted Average Shares 12.42 12.42 11.08 11.08
Diluted EPS Excluding Extraordinary Items -1.68 -1.68 -2.55 -2.55
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS -0.209 -0.209 -0.349 -0.349
* In Millions of CHF (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RLFB Comments

Write your thoughts about Relief Therapeutics Holding SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Carlos Medina
Carlos Medina Jan 05, 2022 10:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Reason for the spike? Still pump and dump?
Laurent Loboss Badoud
Laurent Loboss Badoud Jan 05, 2022 10:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Relief Therapeutics: Nrx wants to patent its anti-COVID formulation of aviptadil
Marco Singarella
Marco Singarella Jan 05, 2022 10:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Still pump and dump. Is it now a good time to buy?
Mohamed Nedif
Mohamed Nedif Nov 12, 2021 3:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.relieftherapeutics.com/newsblog/relief-reports-that-its-u-s-collaboration-partner-has-announced-it-has-received-a-u-s-food-and-drug-administration-review-of-aviptadil-manufacturing-information
Carlos Medina
Carlos Medina Oct 20, 2021 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
With the lawsuit it's pretty much the end for this thing, right?
Marco Singarella
Marco Singarella Oct 20, 2021 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Which lawsuit?
Marco Singarella
Marco Singarella Oct 20, 2021 11:21AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just found this now. Yes sounds the end
Marco Singarella
Marco Singarella Sep 22, 2021 3:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good time to buy now. will definitely go up in the next few weeks
Carlos Medina
Carlos Medina Sep 22, 2021 3:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Based on?
Jaroslav Kovacik
Jaroslav Kovacik Sep 07, 2021 10:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2q 2022 gona bi big
Douglas Boggs
Douglas Boggs Jul 29, 2021 7:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lots of potential but Still no revenue to report
Carlos Medina
Carlos Medina Jul 29, 2021 6:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock is puzzling. No updates, suddenly up 20.30% out of the blue. This week, it's secured more funding, completed acquisitions, Aviptadil gets approval in Georgia plus commercial formulation... and the stock is down about 6-7% .... SMH x-/
Carlos Medina
Carlos Medina Jul 27, 2021 3:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ok this is bigNRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
Jason Conway
Jason Conway Jul 27, 2021 3:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Turns out it wasn’t that big…
Krava Tsakosh
Krava Tsakosh Jun 08, 2021 10:48AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
That's a nice start of the week
Carlos Medina
Carlos Medina May 21, 2021 12:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock keeps doing this, falls gradually and then it's pumped o and volume another 20% only to fall again due to lack of news and meaningful updates.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email